Silexon partners with Excelra for AI-driven drug discovery research

By The Science Advisory Board staff writers

December 6, 2021 -- Silexon is partnering with Excelra, deploying Excelera's global online structure activity relationship (Gostar) database to strengthen its artificial intelligence (AI)-driven drug discovery and biopharmaceutical research platform.

Excelra will provide absorption, distribution, metabolism, and excretion data, as well as binding assay datasets, from its database to Silexon. Gostar's database includes information encompassing more than 8 million compounds and 28 million structure activity relationship-associated data points.

Silexon uses real-world biological data and machine-learning capabilities to aid in drug design. Silexon will use Gostar for drug discovery and biopharmaceutical research. This collaboration has the potential to shorten the time to market for new lifesaving drugs, according to the firms.

No financial terms of the agreement were disclosed.

New machine-learning approach promises to speed drug design
A new approach to machine learning outperformed current machine-learning methods in drug design, demonstrating its potential in speeding up the drug discovery...
Excelra launches updated Gostar chemistry insights engine
Data science firm Excelra has released an updated version of its Gostar chemistry insights engine. The updated version includes a more advanced search...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter